Abstract | BACKGROUND: METHODS: We randomly assigned 22 patients with a first acute MI, who underwent successful direct PCI, to EN, 50 mug, i.c., or placebo (PL), administered immediately after reperfusion. VA were manually edited and counted from 24-hour Holter recordings begun upon hospital admission. RESULTS: There were no significant between-groups differences in clinical characteristics. Mean RR interval before and after PCI, and the incidence of VA before PCI were similar in both groups. After PCI the incidence of reperfusion-induced VA was significantly lower in the EN-treated group (VPB/h: PL 29.9 +/- 12 vs EN 43.2 +/- 42, P < 0.05; couplets/h: EN 0.9 +/- 0.7 vs PL 4.1 +/- 5.0, P < 0.01; triplets/h: EN 0.3 +/- 0.2 vs PL 1.2 +/- 1.5, P < 0.05; ventricular tachycardia/h: EN 0.3 +/- 0.1 vs PL 0.8 +/- 0.5, P < 0.01). CONCLUSIONS: Compared with PL, i.c. EN significantly lowered the incidence of reperfusion-associated VA. This previously unrecognized antiarrhythmic effect might be an important therapeutic benefit conferred by ACE inhibitors, beyond limitation of infarct size.
|
Authors | Hendrik Bonnemeier, Ulrich Schäfer, Jasmin Ortak, Thomas Kurz, Hugo A Katus, Gert Richardt, Heribert Schunkert |
Journal | Pacing and clinical electrophysiology : PACE
(Pacing Clin Electrophysiol)
Vol. 30 Suppl 1
Pg. S160-5
(Jan 2007)
ISSN: 0147-8389 [Print] United States |
PMID | 17302696
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antihypertensive Agents
- Enalapril
|
Topics |
- Aged
- Angioplasty, Balloon, Coronary
- Antihypertensive Agents
(administration & dosage)
- Arrhythmias, Cardiac
(etiology, prevention & control)
- Coronary Artery Disease
(complications, therapy)
- Enalapril
(administration & dosage)
- Female
- Humans
- Male
- Middle Aged
- Myocardial Infarction
- Myocardial Reperfusion
- Prospective Studies
|